Cargando…
Clinical Evidence for the Choice of the Direct Oral Anticoagulant in Patients with Atrial Fibrillation According to Creatinine Clearance
Atrial fibrillation (AF) often coexists with chronic kidney disease (CKD), which confer to the patient a higher risk of both thromboembolic and hemorrhagic events. Oral anticoagulation therapy, nowadays preferably with direct oral anticoagulants (DOACs), represents the cornerstone for ischemic strok...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003529/ https://www.ncbi.nlm.nih.gov/pubmed/33808739 http://dx.doi.org/10.3390/ph14030279 |
_version_ | 1783671711293505536 |
---|---|
author | Vio, Riccardo Proietti, Riccardo Rigato, Matteo Calò, Lorenzo Arcangelo |
author_facet | Vio, Riccardo Proietti, Riccardo Rigato, Matteo Calò, Lorenzo Arcangelo |
author_sort | Vio, Riccardo |
collection | PubMed |
description | Atrial fibrillation (AF) often coexists with chronic kidney disease (CKD), which confer to the patient a higher risk of both thromboembolic and hemorrhagic events. Oral anticoagulation therapy, nowadays preferably with direct oral anticoagulants (DOACs), represents the cornerstone for ischemic stroke prevention in high-risk patients. However, all four available DOACs (dabigatran, apixaban, rivaroxaban and edoxaban) are eliminated by the kidneys to some extent. Reduced kidney function facilitates DOACs accumulation and, therefore, different dose reductions are required, with slight differences between American and European recommendations especially in case of severe renal impairment (creatinine clearance < 30 mL/min). Overall, the use of DOACs in patients with non-end stage CKD and AF is effective similarly to warfarin, showing a better safety profile. The management of thromboembolic risk among patients with AF on dialysis remains challenging, as warfarin effectiveness for stroke prevention in this population is questionable and retrospective data on apixaban need to be confirmed on a larger scale. In kidney transplant recipients, DOACs may provide a potentially safer option compared to warfarin, but co-administration with immunosuppressants is a matter of concern. |
format | Online Article Text |
id | pubmed-8003529 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80035292021-03-28 Clinical Evidence for the Choice of the Direct Oral Anticoagulant in Patients with Atrial Fibrillation According to Creatinine Clearance Vio, Riccardo Proietti, Riccardo Rigato, Matteo Calò, Lorenzo Arcangelo Pharmaceuticals (Basel) Review Atrial fibrillation (AF) often coexists with chronic kidney disease (CKD), which confer to the patient a higher risk of both thromboembolic and hemorrhagic events. Oral anticoagulation therapy, nowadays preferably with direct oral anticoagulants (DOACs), represents the cornerstone for ischemic stroke prevention in high-risk patients. However, all four available DOACs (dabigatran, apixaban, rivaroxaban and edoxaban) are eliminated by the kidneys to some extent. Reduced kidney function facilitates DOACs accumulation and, therefore, different dose reductions are required, with slight differences between American and European recommendations especially in case of severe renal impairment (creatinine clearance < 30 mL/min). Overall, the use of DOACs in patients with non-end stage CKD and AF is effective similarly to warfarin, showing a better safety profile. The management of thromboembolic risk among patients with AF on dialysis remains challenging, as warfarin effectiveness for stroke prevention in this population is questionable and retrospective data on apixaban need to be confirmed on a larger scale. In kidney transplant recipients, DOACs may provide a potentially safer option compared to warfarin, but co-administration with immunosuppressants is a matter of concern. MDPI 2021-03-19 /pmc/articles/PMC8003529/ /pubmed/33808739 http://dx.doi.org/10.3390/ph14030279 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Review Vio, Riccardo Proietti, Riccardo Rigato, Matteo Calò, Lorenzo Arcangelo Clinical Evidence for the Choice of the Direct Oral Anticoagulant in Patients with Atrial Fibrillation According to Creatinine Clearance |
title | Clinical Evidence for the Choice of the Direct Oral Anticoagulant in Patients with Atrial Fibrillation According to Creatinine Clearance |
title_full | Clinical Evidence for the Choice of the Direct Oral Anticoagulant in Patients with Atrial Fibrillation According to Creatinine Clearance |
title_fullStr | Clinical Evidence for the Choice of the Direct Oral Anticoagulant in Patients with Atrial Fibrillation According to Creatinine Clearance |
title_full_unstemmed | Clinical Evidence for the Choice of the Direct Oral Anticoagulant in Patients with Atrial Fibrillation According to Creatinine Clearance |
title_short | Clinical Evidence for the Choice of the Direct Oral Anticoagulant in Patients with Atrial Fibrillation According to Creatinine Clearance |
title_sort | clinical evidence for the choice of the direct oral anticoagulant in patients with atrial fibrillation according to creatinine clearance |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003529/ https://www.ncbi.nlm.nih.gov/pubmed/33808739 http://dx.doi.org/10.3390/ph14030279 |
work_keys_str_mv | AT vioriccardo clinicalevidenceforthechoiceofthedirectoralanticoagulantinpatientswithatrialfibrillationaccordingtocreatinineclearance AT proiettiriccardo clinicalevidenceforthechoiceofthedirectoralanticoagulantinpatientswithatrialfibrillationaccordingtocreatinineclearance AT rigatomatteo clinicalevidenceforthechoiceofthedirectoralanticoagulantinpatientswithatrialfibrillationaccordingtocreatinineclearance AT calolorenzoarcangelo clinicalevidenceforthechoiceofthedirectoralanticoagulantinpatientswithatrialfibrillationaccordingtocreatinineclearance |